Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Panobinostat in Relapsed/Refractory DLBCL
NCT00978432Phase 2Terminated
- Start
- Feb 2012
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus and panobinostat in diffuse large B-cell lymphoma (DLBCL). Started Feb 2012; status: terminated.
02
Drugs
everolimuspanobinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00978432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00978432.